AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.21, $0.08 better than the analyst estimate of $1.13. Revenue for the quarter came in at $5.59 billion versus the consensus estimate of $5.57 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.